STAT+: Pharmalittle: GSK CEO warns U.K. pharma industry is at a ‘tipping point’; Gavi tussles with vaccine makers over refunds
Top of the morning to you. And a fine one it is. Sunny skies and…
Category: Pharma
Opinion: Generics: a missing piece in China’s Covid-19 crisis response
China’s massive Covid-19 crisis, sparked in part by the country’s rolling back its strict zero-Covid…
STAT+: Pharmalittle: Pfizer projects lower revenue from Covid-19 products; Medicare eyes policy for paying less for accelerated-approval drugs
Top of the morning to you. The middle of the week is upon us and,…
STAT+: Pharmalittle: Amgen pricing for Humira biosimilar may not help patients; pharma wins court battle over drug discount program
Hello, everyone, and how are you this morning? We are just fine, thank you, although…
STAT+: Amgen pricing for its Humira biosimilar may benefit PBMs and insurers more than patients
Underscoring the opaque and confusing nature of pharmaceutical pricing, Amgen announced long-awaited pricing for its…
Opinion: A watershed year for biosimilars — if regulators and policymakers step up
January 31 is set to mark the start of a watershed year for the biosimilars…
STAT+: U.K. lawmakers urge Pfizer not to raise the price of its Covid-19 vaccine
Several U.K. lawmakers have asked Pfizer not to raise the price of its Covid-19 vaccine,…
STAT+: Pharma wins a key round in a court battle with hospitals over a drug discount program
In a victory for the pharmaceutical industry, a federal appeals court ruled drug companies have…
STAT+: Pharmalittle: Pfizer is scolded by U.K. industry group over CEO’s remarks on vaccination; Amgen to lay off 300 U.S. employees
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: ‘A classic case’: A legal expert on why lawsuits challenging abortion pill restrictions may succeed
A pair of lawsuits was filed last week challenging restrictions on access to abortion pills…
Opinion: As it turns 40, the Orphan Drug Act for rare diseases needs a refresh
This month marks the 40th anniversary of the Orphan Drug Act. Since it was signed…
.jpg)
STAT+: Pfizer is scolded by a U.K. trade group for remarks its CEO made about vaccination
After weeks of deliberation, Pfizer was scolded by a U.K. pharmaceutical industry trade group after…
STAT+: Pharmalittle: Some Republicans push to probe Pfizer over Covid-19 ‘mutations’; Warren urges FTC to probe pharma mergers
And so, another working week will soon draw to a close. Not a moment too…
It’s easy to buy flavored vapes in California, even in cities with longtime bans
LOS ANGELES – California cities are supposed to be cracking down on sales of flavored…
STAT+: A bellwether for biosimilars: Why the new competition for Humira matters to pharma, payers, and patients
After months of anticipation, the first biosimilar version of Humira will become available next week…
STAT+: Warren urges the FTC to scrutinize two pharma mergers over “anti-competitive” practices
In her latest bid to address prescription drug prices, U.S. Sen. Elizabeth Warren (D-Mass.) is…
After nearly 4 years of deliberation, FDA punts on how to regulate CBD
WASHINGTON — The FDA is giving up on trying to figure out a way to…
STAT+: Pharmalittle: Strange bedfellows lobby for Medicare coverage of obesity drugs; FDA working with WHO to probe cough syrups
Hello, everyone, and how are you this morning? We are doing just fine, thank you,…
Watch: How do the new obesity drugs work?
Drugs like Wegovy and Ozempic are rapidly growing in popularity as weight-loss treatments. These medications…
STAT+: Novartis and Lilly turn to nonprofit, instead of FDA, to resolve dispute over drug ad
In a rare move, the Better Business Bureau National Programs settled a dispute between two…
STAT+: Pharmalittle: Merck ends late-stage trial for Keytruda in prostate cancer; doctor group says 60 Minutes segment on Wegovy was an ad
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT+: Novartis is fined by Belgian regulators for anticompetitive practices over an eye treatment
Belgian anti-trust regulators fined Novartis nearly $2.8 million for making misleading statements about a treatment…
Opinion: Making naloxone available over the counter won’t solve the overdose crisis — but it will help
The Food and Drug Administration aims to conduct priority reviews of at least two product…
The drug was meant to save children’s lives. Instead, they’re dying
Emily was combing her baby daughter’s hair when she first felt the lumps. It was…
STAT+: Doctors’ group complains that 60 Minutes segment on Wegovy was really just an ad
A physicians’ group has filed a complaint with the U.S. Food and Drug Administration alleging…
STAT+: Pharmalittle: Amazon adds $5 monthly generic drug subscription; PhRMA ends lobbying contract with brother of White House official
Rise and shine, everyone, another busy day is on the way. We can tell thanks…
STAT+: Many pediatric drug study results were never posted to a U.S. government database
Amid ongoing controversy over clinical trial transparency, a new analysis found that results of 43…
STAT+: Despite court ruling, FDA will continue with its approach to approving orphan drug exclusivity
In an unexpected move, the U.S. Food and Drug Administration will continue to apply exclusive…
STAT+: Pharmalittle: Obesity guidelines cause backlash; Bayer is pushed to spin off its consumer health business
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: FTC wants ‘pharma bro’ Martin Shkreli held in contempt for violating lifelong ban on working in pharma
The U.S. Federal Trade Commission asked a federal judge to hold “pharma bro” Martin Shkreli…
STAT+: Pharmalittle: FDA rejects Lilly application for Alzheimer’s drug; Sanofi offers a warranty for a medicine
And so, another working week will soon draw to a close. Not a moment too…
.jpg)
Opinion: Even with lawsuits and copay caps, will insulin ever be affordable?
In an attempt to tackle the root causes of the inflated cost of insulin, the…
STAT+: ‘A cascade of failures’: FDA cites Indian drugmaker for numerous quality control problems
In a stunning rebuke, the U.S. Food and Drug Administration accused a drugmaker of a…
STAT+: Pallone pushes NIH and FDA to disclose steps being taken to ensure clinical trial results are reported
A Democratic lawmaker is demanding to know what steps the U.S. Food and Drug Administration…
STAT+: For only the second time, a big drugmaker offers a warranty on a medicine
In a bid to blunt competition and address rising drug costs, Sanofi is offering a…
STAT+: Will the European Union give vouchers to pharma to develop badly needed antibiotics?
Amid rising concern over antibiotic resistance, a battle is brewing in Europe over a proposal…
STAT+: Pharmalittle: India regulator finds 5% of drug samples are substandard; EMA claims new clinical trial registry is fixed
Hello, everyone, and how are you today? A steely gray sky is hovering this morning…
STAT+: Pharmalittle: HIV vaccine study is stopped early; Merck has a plan to combat carcinogen found in diabetes drugs
Top of the morning to you. The middle of the week is upon us and,…
Mix-it-yourself Wegovy? Some are trying risky sources for weight-loss drugs
With a few clicks, Daniel added the chemical to his online cart and ordered it….
STAT+: Major purchasers predict expensive new therapies will keep driving drug price hikes
More than two dozen big buyers of prescription medicines expect that prices will rise by…
STAT+: Pfizer says it will widen access to hundreds of off-patent medicines in poor countries
In another bid to widen access to its medical products, Pfizer plans to provide roughly…
STAT+: Pharmalittle: Lilly and AbbVie exit U.K. drug-pricing program; J&J scales back Covid-19 vaccine production
Good morning, everyone, and welcome to another working week, which is only getting started on…
STAT+: Large health insurers lowered barriers to fair access to some drugs, analysis finds
Most of the largest health plans in the U.S. generally provide “fair access” to 19…
Opinion: Stop blaming Biogen for putting profit at the expense of patients. Blame the systems that enabled it
Two congressional committees recently released damning results of an 18-month investigation into the Food and…
STAT+: Pharmalittle: Pharma prioritizes biologics over pills due to drug-pricing law; former Takeda employee accused of creating fake consulting firm
And so, another working week will soon draw to a close. Not a moment too…
STAT+: California is the latest state to sue drugmakers and PBMs over insulin pricing
The California attorney general has filed a lawsuit accusing several drugmakers and pharmacy benefit managers…
‘We become millionaires and we retire babe’: Former Takeda worker and boyfriend accused of $2.3 million scam of drug firm
A high-ranking former technology officer at Takeda Pharmaceutical’s US headquarters in Massachusetts and her boyfriend…
STAT+: Pharmalittle: HHS readying details for Medicare drug-price negotiations; doctors urge FDA to hold expert meeting before approving Alzheimer’s drug
Top of the morning to you. Gray skies are hovering over the Pharmalot campus right…
Opinion: Democratizing drug development will be a win for all
In 1992, the film Lorenzo’s Oil celebrated the true story of two parents who, despite…
STAT+: Physicians group urges FDA to convene expert panel before finally approving an Alzheimer’s drug
A physicians group is urging the Food and Drug Administration to hold an expert panel…